HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Post-Pandemic Stocks

890.999

+0.6250.07%

Number of Gainers:5

Number of Losers:11

Number of Flat:2

PE:- -

High:909.667

Open:890.747

Low:887.715

Close:890.374

Loading ...

Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application for Toripalimab From Nmpa

THOMSON REUTERS

BYD Electronic International Q1 Net Income RMB 622.1 Million

THOMSON REUTERS

Sino Biopharmaceutical Gets FDA Nod to Market Cancer Drug

MT Newswires Live

Sino Biopharmaceutical - Approval for Marketing of Penpulimab Injection by US FDA

THOMSON REUTERS

CSPC Innovation Pharmaceutical Swings to Q1 Loss

MT Newswires Live

BRIEF-Sinopharm Group Posts Qtrly Net Profit Attributable RMB328 Million For Sinopharm Accord

Rpt-Sinopharm Group - Qtrly Net Profit Attributable RMB328 Mln for Sinopharm Accord

THOMSON REUTERS

Sinopharm Group Q1 Revenue RMB 18,294 Million

THOMSON REUTERS

Sihuan Pharmaceutical Unit's Diabetes Drug Gets Registration Approval in China

MT Newswires Live

Ping an Health Reports 25.8% Year-on-Year Revenue Growth in Q1 2025, With Profitability Accelerating

THOMSON REUTERS

BRIEF-Sihuan Pharma Says Dapagliflozin Tablets Obtained Drug Registration Approval From NMPA

BRIEF-Ping An Healthcare And Technology Posts Qtrly Net Profit RMB33.2 Million

Sihuan Pharma - Dapagliflozin Tablets Developed by Huisheng Biopharmaceutical Obtained Drug Registration Approval From Nmpa

THOMSON REUTERS

Xinhua Pharmaceutical Gets Registration Certificate for Alzheimer's Dementia Drug in China

MT Newswires Live

CSPC Pharmaceutical Gets FDA Nod for Cancer Cachexia Drug Trial

MT Newswires Live

Ping an Healthcare and Technology - Qtrly Net Profit RMB33.2 Mln

THOMSON REUTERS

Ascletis Pharma's Phase 1B Trial for Obesity Tablets Showed Favorable Safety Results

MT Newswires Live

CSPC Pharmaceutical Gets China Nod for Diabetes Mellitus Combination Drug Trial

MT Newswires Live

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral Glp-1R Agonist Asc30 and Submission of 13-Week Phase Iia Study Protocol to FDA

THOMSON REUTERS

BRIEF-CSPC Pharmaceutical Says JMT203 (Anti-Gfral Monoclonal Antibody) Obtains Clinical Trial Approval In U.S.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1515/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":890.99915,"timestamp":1745568501389,"preClose":890.3739,"halted":0,"volume":435899656,"delay":0,"changeRate":0.000702,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0.625244,"latestTime":"04-25 16:00:00","open":890.74744,"high":909.6669,"low":887.7149,"amount":3129554435,"amplitude":0.024655,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745803800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745544600000,1745553600000],[1745557200000,1745568000000]],"pbRate":1.60334,"peRate":21.395071,"turnoverRate":0.005773,"increases":5,"decrements":12,"flats":1,"marketCap":614989925952,"floatMarketCap":505251641024},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":909.6669,"amplitude":0.024655,"preClose":890.3739,"low":887.7149,"pbRate":"1.60334","latestPrice":890.99915,"volume":435899656,"delay":0,"open":890.74744,"prevYearClose":787.97723,"prevWeekClose":849.427,"prevMonthClose":870.015,"prevQuarterClose":870.015,"fiveDayClose":838.217,"twentyDayClose":875.086,"sixtyDayClose":761.95,"secType":"PLATE","market":"HK","turnoverRate":0.005773,"peRate":21.395071,"marketCap":614989925952,"floatMarketCap":505251641024,"timestamp":1745568501389,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":5,"down":11,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530813951","title":"Shanghai Junshi Biosciences -  Approval of Supplemental New Drug Application for Toripalimab From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2530813951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530813951?lang=en_us&edition=fundamental","pubTime":"2025-04-25 19:40","pubTimestamp":1745581251,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R31PE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688180","BK1515","01877","BK1583","BK0239","BK1161"],"gpt_icon":0},{"id":"2530725999","title":"BYD Electronic International Q1 Net Income RMB 622.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2530725999","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530725999?lang=en_us&edition=fundamental","pubTime":"2025-04-25 16:32","pubTimestamp":1745569947,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nPLXD42C37:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1504","BK1580","00285","LU0274383008.USD","LU0348766576.USD","BK1149","BK1589","BK1515","BK1540","LU0348767384.USD","BK1607","BK1582"],"gpt_icon":0},{"id":"2530929187","title":"Sino Biopharmaceutical Gets FDA Nod to Market Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2530929187","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530929187?lang=en_us&edition=fundamental","pubTime":"2025-04-25 13:55","pubTimestamp":1745560557,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical's  co-developed penpulimab injection secured marketing approval from the US Food and Drug Administration, a Friday Hong Kong bourse filing said.The drug is indicated either in combination with cisplatin or carboplatin and gemcitabine, or as a single agent, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01177","BK1191","BK1589","BK1521","BK1515"],"gpt_icon":0},{"id":"2530947958","title":"Sino Biopharmaceutical - Approval for Marketing of Penpulimab Injection by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2530947958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530947958?lang=en_us&edition=fundamental","pubTime":"2025-04-25 12:17","pubTimestamp":1745554658,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R23K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1521","01177","BK1589","BK1515","BK1191"],"gpt_icon":0},{"id":"2529988775","title":"CSPC Innovation Pharmaceutical Swings to Q1 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2529988775","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529988775?lang=en_us&edition=fundamental","pubTime":"2025-04-24 19:38","pubTimestamp":1745494689,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  incurred an attributable loss of 26.9 million yuan in the first quarter, compared with an attributable profit of 79.1 million yuan a year prior, a Wednesday Hong Kong filing by parent CSPC Pharmaceutical  said.Loss per share in the quarter was 0.0192 yuan, while the company made earnings per share of 0.0676 yuan in the first quarter of 2024.The pharmaceutical company saw a 9.9% drop in revenue to 472 million yuan in the three months from 524.1 million yuan in the year-ago period.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1226287529.USD","LU1807302812.USD","01093","BK1515","IE00B543WZ88.USD","LU0326950275.SGD","LU1226287792.SGD","BK1191","LU0140636845.USD","LU1008478684.HKD","LU0067412154.USD","LU1226287875.USD","LU1960683339.HKD","IE0008368742.USD","IE00B031HY20.USD","LU1951186391.HKD","LU0880133367.SGD","300765","BK0226","LU0072913022.USD","LU1226288253.USD","LU1152091754.HKD","IE0008369823.USD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU1152091168.USD","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU1226288170.HKD","SG9999004220.SGD","BK1521","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2529608701","title":"BRIEF-Sinopharm Group Posts Qtrly Net Profit Attributable RMB328 Million For Sinopharm Accord","url":"https://stock-news.laohu8.com/highlight/detail?id=2529608701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529608701?lang=en_us&edition=fundamental","pubTime":"2025-04-24 17:54","pubTimestamp":1745488471,"startTime":"0","endTime":"0","summary":"BRIEF-Sinopharm Group Posts Qtrly Net Profit Attributable RMB328 Million For Sinopharm AccordApril 24  - Sinopharm Group Co Ltd 1099.HK:Q1 REVENUE RMB 18,294 MILLION FOR SINOPHARM ACCORDQTRLY NET PROFIT ATTRIBUTABLE RMB328 MILLION FOR SINOPHARM ACCORDFurther company coverage: 1099.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nL8N3R20VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0185","LU1115378108.SGD","01099","000028","BK0250","BK0175","BK0196","BK0082","BK0010","BK1197","LU0640798160.USD","BK0028","BK1515","BK1500"],"gpt_icon":0},{"id":"2529267029","title":"Rpt-Sinopharm Group - Qtrly Net Profit Attributable RMB328 Mln for Sinopharm Accord","url":"https://stock-news.laohu8.com/highlight/detail?id=2529267029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529267029?lang=en_us&edition=fundamental","pubTime":"2025-04-24 17:54","pubTimestamp":1745488471,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nL8N3R20VD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01099","BK0028","BK0082","LU1115378108.SGD","BK0175","BK1500","BK1197","BK0250","BK0010","BK0188","BK0196","BK1515","000028","LU0640798160.USD","BK0185"],"gpt_icon":0},{"id":"2529670463","title":"Sinopharm Group Q1 Revenue RMB 18,294 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2529670463","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529670463?lang=en_us&edition=fundamental","pubTime":"2025-04-24 17:50","pubTimestamp":1745488233,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nPLXC26076:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1197","BK1500","01099","LU1115378108.SGD","BK1515","LU0640798160.USD"],"gpt_icon":0},{"id":"2529672710","title":"Sihuan Pharmaceutical Unit's Diabetes Drug Gets Registration Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2529672710","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529672710?lang=en_us&edition=fundamental","pubTime":"2025-04-24 17:36","pubTimestamp":1745487415,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration granted drug registration approval for Sihuan Pharmaceutical  subsidiary Huisheng Biopharmaceutical's Dapagliflozin tablets for the treatment of type 2 diabetes in adult patients.The medication also passed China's consistency evaluation of quality and efficacy of generic drugs, according to a Wednesday filing with the Hong Kong Exchange.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1600","BK1191","BK1515","BK1593","00460"],"gpt_icon":0},{"id":"2529626500","title":"Ping an Health Reports 25.8% Year-on-Year Revenue Growth in Q1 2025, With Profitability Accelerating","url":"https://stock-news.laohu8.com/highlight/detail?id=2529626500","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529626500?lang=en_us&edition=fundamental","pubTime":"2025-04-24 15:30","pubTimestamp":1745479840,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA1M8MJS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1142","BK1617","BK1615","BK1247","BK1515","01833","BK1571","BK1219"],"gpt_icon":0},{"id":"2529631655","title":"BRIEF-Sihuan Pharma Says Dapagliflozin Tablets Obtained Drug Registration Approval From NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2529631655","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529631655?lang=en_us&edition=fundamental","pubTime":"2025-04-23 23:26","pubTimestamp":1745421990,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharma Says Dapagliflozin Tablets Obtained Drug Registration Approval From NMPAApril 23 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:DAPAGLIFLOZIN TABLETS DEVELOPED BY HUI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R10YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1191","BK1593","BK1515","BK1600"],"gpt_icon":0},{"id":"2529463165","title":"BRIEF-Ping An Healthcare And Technology Posts Qtrly Net Profit RMB33.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2529463165","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529463165?lang=en_us&edition=fundamental","pubTime":"2025-04-23 23:25","pubTimestamp":1745421956,"startTime":"0","endTime":"0","summary":"BRIEF-Ping An Healthcare And Technology Posts Qtrly Net Profit RMB33.2 MillionApril 23 (Reuters) - Ping An Healthcare and Technology Co Ltd 1833.HK:QTRLY NET PROFIT RMB33.2 MILLIONQTRLY TOTAL REVENUE OF RMB1,062.5 MILLIONFurther company coverage: 1833.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R02M9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1247","BK1219","BK1617","BK1615","BK1571","01833","BK1142","BK1515"],"gpt_icon":0},{"id":"2529050052","title":"Sihuan Pharma - Dapagliflozin Tablets Developed by Huisheng Biopharmaceutical Obtained Drug Registration Approval From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2529050052","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529050052?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:38","pubTimestamp":1745411923,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R10YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1600","BK1191","00460","BK1593"],"gpt_icon":0},{"id":"2529502370","title":"Xinhua Pharmaceutical Gets Registration Certificate for Alzheimer's Dementia Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2529502370","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529502370?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:05","pubTimestamp":1745409917,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  received the drug registration certificate for its memantine hydrochloride oral solution from China's National Medical Products Administration, a Wednesday filing with the Hong Kong bourse said.The drug is used to treat moderate to severe Alzheimer's dementia, according to the pharmaceutical firm.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0164","BK1191","000756","BK1515","00719"],"gpt_icon":0},{"id":"2529257613","title":"CSPC Pharmaceutical Gets FDA Nod for Cancer Cachexia Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2529257613","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529257613?lang=en_us&edition=fundamental","pubTime":"2025-04-23 17:49","pubTimestamp":1745401793,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical  obtained clinical trial approval for JMT203, developed by unit Shanghai JMT-BIO Technology, from the U.S. Food and Drug Administration , a Tuesday filing with the Hong Kong bourse said.The drug, which had obtained trial approval from the National Medical Products Administration in June 2023, is currently undergoing trials in China.The indication for this approval is cancer cachexia.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B543WZ88.USD","01093","LU1226288253.USD","LU1993786604.SGD","IE00B5MMRT66.SGD","BK1515","LU0326950275.SGD","LU0072913022.USD","IE0008369823.USD","LU1226287875.USD","BK1521","LU1807302812.USD","IE0008368742.USD","BK1191","LU1960683339.HKD","LU1226288170.HKD","LU0067412154.USD","LU0880133367.SGD","IE00B031HY20.USD","SG9999004220.SGD","LU1226287792.SGD","LU0140636845.USD","LU1008478684.HKD","LU1152091754.HKD","IE00BZ08YT58.USD","LU1152091168.USD","LU1226287529.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU0501845795.SGD","LU1951186391.HKD"],"gpt_icon":0},{"id":"2529277985","title":"Ping an Healthcare and Technology - Qtrly Net Profit RMB33.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2529277985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529277985?lang=en_us&edition=fundamental","pubTime":"2025-04-23 17:16","pubTimestamp":1745399794,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R02M9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1617","BK1219","BK1515","BK1571","BK1615","01833","BK1142","BK1247"],"gpt_icon":0},{"id":"2529522780","title":"Ascletis Pharma's Phase 1B Trial for Obesity Tablets Showed Favorable Safety Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2529522780","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529522780?lang=en_us&edition=fundamental","pubTime":"2025-04-23 17:02","pubTimestamp":1745398942,"startTime":"0","endTime":"0","summary":"Ascletis Pharma  said its phase 1B multiple ascending dose study for its ASC30 tablets for obesity showed positive topline results, according to a Wednesday filing with the Hong Kong bourse.The drug showed a favorable safety profile, with gastrointestinal-related adverse events mild and short-lived, the filing said.Trial enrollees did not show serious adverse events, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","01672","BK1574","BK1161"],"gpt_icon":0},{"id":"2529547495","title":"CSPC Pharmaceutical Gets China Nod for Diabetes Mellitus Combination Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2529547495","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529547495?lang=en_us&edition=fundamental","pubTime":"2025-04-23 15:25","pubTimestamp":1745393101,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical  has obtained approval to conduct a clinical trial of Prusogliptin and Metformin Extended-Release Tablets from China's National Medical Products Administration, a Tuesday filing with the Hong Kong bourse said.The indication for the trial approval is for use as an adjunct to diet and exercise in the treatment of adult patients with type 2 diabetes mellitus.The product is the world's first fixed-dose combination formulation of prusogliptin and metformin hydrochloride approved for clinical trials.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1951186391.HKD","IE00BZ08YR35.GBP","BK1191","SG9999004220.SGD","01093","LU1226288170.HKD","IE00BZ08YS42.EUR","IE0008368742.USD","LU0501845795.SGD","IE00B543WZ88.USD","LU0326950275.SGD","LU1226288253.USD","LU1226287529.USD","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","BK1515","LU0140636845.USD","IE00B031HY20.USD","LU1226287875.USD","LU1008478684.HKD","LU0880133367.SGD","LU1152091168.USD","BK1521","LU1807302812.USD","LU1152091754.HKD","LU1226287792.SGD","LU1960683339.HKD","IE0008369823.USD","LU1993786604.SGD","LU0067412154.USD","LU0072913022.USD"],"gpt_icon":0},{"id":"2529456782","title":"Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral Glp-1R Agonist Asc30 and Submission of 13-Week Phase Iia Study Protocol to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2529456782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529456782?lang=en_us&edition=fundamental","pubTime":"2025-04-23 07:30","pubTimestamp":1745364602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA702MKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","01672","BK1161","BK1515"],"gpt_icon":0},{"id":"2529582459","title":"BRIEF-CSPC Pharmaceutical Says JMT203 (Anti-Gfral Monoclonal Antibody) Obtains Clinical Trial Approval In U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2529582459","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529582459?lang=en_us&edition=fundamental","pubTime":"2025-04-22 22:21","pubTimestamp":1745331671,"startTime":"0","endTime":"0","summary":"BRIEF-CSPC Pharmaceutical Says JMT203  Obtains Clinical Trial Approval In U.S.April 22  - CSPC Pharmaceutical Group Ltd 1093.HK:JMT203  OBTAINS CLINICAL TRIAL APPROVAL IN U.S.Further company coverage: 1093.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3QZ25F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1993786604.SGD","LU1226288253.USD","LU1152091754.HKD","LU1951186391.HKD","LU0880133367.SGD","BK1515","IE00BZ08YS42.EUR","LU0072913022.USD","LU0067412154.USD","LU1807302812.USD","LU1152091168.USD","LU0501845795.SGD","IE00B543WZ88.USD","IE00B031HY20.USD","LU1226287875.USD","LU1226288170.HKD","IE00BZ08YT58.USD","01093","LU0140636845.USD","SG9999004220.SGD","LU0326950275.SGD","LU1226287529.USD","LU1226287792.SGD","LU1960683339.HKD","BK1521","BK1191","IE00BZ08YR35.GBP","IE0008369823.USD","IE0008368742.USD","IE00B5MMRT66.SGD","LU1008478684.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}